Korean J Vet Res > Volume 65(3); 2025 > Article
Anah, Anah, and Mayih: Evaluation of the efficacy of zinc oxide nanoparticles on Cryptosporidium parvum in experimentally infected laboratory mice

Abstract

The effectiveness of zinc oxide nanoparticles (ZnO-NPs) on Cryptosporidium parvum was investigated by infecting laboratory mice with a dose of 1 × 103 oocysts/mouse. Each group was given 1 mL of the specified dose and then administered ZnO-NPs at concentrations of 5, 15, and 20 mg/kg. The nested-polymerase chain reaction revealed the amplification of the heat shock protein gene of C. parvum in all samples that were identified microscopically using Ziehl-Neelsen staining. The current study indicated the use of ZnO-NPs as a treatment for mice infected with C. parvum oocysts for a week. The effects of the three concentrations varied in reducing the number of oocysts excreted in the feces of experimentally infected mice. The 20 mg/kg concentration was the best concentration becauseit completely reduced the oocysts on the fifth day, with a therapeutic efficiency of 100%. At this concentration, the mice completely stopped shedding oocysts compared to the positive control group, which continued to shed oocysts until the seventh day. This was also the closest concentration to the group treated with nitazoxanid, which achieved a therapeutic efficiency of 100% on the fourth day of treatment. At 15 mg/kg, therapeutic efficacy was achieved on the sixth and seventh days of treatment at a rate of 96.31% and 100% respectively. By contrast, 5 mg/kg showed low efficacy because the treated mice continued to produce oocysts until the seventh day of treatment.

Introduction

Cryptosporidium parvum is one of the causes of watery diarrhea, whether in humans or animals. This disease causes cryptosporidiosis, which is widespread in varying proportions in developing and developed countries, while some sources indicate high rates of infection in immunosuppressed people [1,2]. C. parvum is also considered a parasite that can reduce growth and lead to mental weakness in infected children at an early age [3,4].
Nanotechnology is one of the most important technologies in modern science and has progressed rapidly. The comprehensiveness and breadth that characterize this technology have met many needs and life requirements [5]. Nanoparticles have unique properties in electronic, magnetic, and chemical catalysis because of their high stability, low reactivity, relatively low toxicity, and multiple forms. These properties have broad applications in various fields of biomedicine, such as the diagnosis and treatment of cancers and other diseases, and industry drugs and gene delivery, and some nanoparticles also have antimicrobial properties for viruses, bacteria, and fungi [6]. Some nanoparticles have been used as antidotes for many pathogens, including protozoan parasites [7,8]. For example, a previous study [9] reported the ability of silver nanoparticles to penetrate the wall of the oocysts of Cryptosporidium, indicating a decrease in the viability of the oocysts at concentrations higher than 0.5 mg/mL.
Zinc is a mineral essential to human health. It is non-toxic but effective even at low concentrations. This mineral plays an important role in most of the body’s biological activities, such as phagocytosis and the production of antibodies and cytokines [10-12]. Considering previous research that indicated the effectiveness of zinc oxide nanoparticles (ZnO-NPs) against Eimeria tenella [13]. In addition, Dkhil et al. [14] reported that giving ZnO-NPs to mice infected with Eimeria papillata helped reduce the harmful effects of oxidative stress. On the other hand, Nazir et al. [15] revealed the effectiveness of zinc nanoparticles against Leishmania tropica, because of the release of reactive oxygen species., Vaidya et al. [16] also examined the effects of silver and ZnO-NPs on the oocysts of C. parvum under different conditions. They reported, that zinc oxide particles were effective in dissolving oocysts and were comparable to freezing and thawing methods. The current study examined the ability of this nanomaterial to oocysts of the C. parvum in experimentally infected mice.

Materials and Methods

Ethical approval

This study was approved by the Committee of the Department of Biology, Faculty of Education, University of AL-Qadisiya (approval number: 578).

Isolation and purification of oocysts of C. parvum

Oocysts of the C. parvum were obtained from some patients who visited Al Diwaniyah Teaching Hospital during the period from 1/11/2024 to 1/1/2025. One hundred stool samples were collected and diagnosed microscopically by making direct smears and stained with modified Ziehl-Neelsen stain.
Oocysts were isolated from stool samples preserved with a potassium dichromate solution using a floatation method and a diabetic solution according to the method reported elsewhere [17]. The number of oocysts per 1 mL of suspension was also calculated using a hemocytometer slide, where the number of oocysts was counted in the eight squares according to the equation below:
Count of oocysts in 1 mL= Count of oocysts in 8 squares8×10,000

Molecular study

Oocysts were diagnosed microscopically using the modified acid stain method. The diagnosis was confirmed molecularly using nested-polymerase chain reaction (N-PCR) technology, where the DNA was extracted according to the method attached to the Taiwanese Presto stool DNA Extraction Kit (Geneaid, Taiwan). The concentration and purity of the extracted DNA were measured using a Nanodrop spectrophotometer by reading the absorbance at 260 to 280 nm. The extracted DNA was stored at 20°C in a refrigerator until a PCR examination was performed. The PCR mixture was then prepared, and the extracted DNA was amplified using special primers to amplify the heat shock protein (HSP70) gene, which was responsible for diagnosing the C. parvum, using N-PCR technology, where two pairs of primers were prepared from Bioneer. The first round of PCR was performed using a pair of C. parvum-HSP70 gene-specific primers: HSP70-F1 5ʼ-TGAGGGTG AGAGAGCCATGA-3ʼ) and HSP70-R1: (5ʼ-GCATACCAC CCT CAG CAGA G-3ʼ). Nested-PCR was performed with a second pair of primers: HSP70-F2 (5ʼATTC CACCAGCAC CA AGA GG -3ʼ, HSP70-R2(5ʼCAGTTTGGTTGTGCTCGAGC-3ʼ). Subsequently, the PCR mixture was transferred to a PCR Thermocycler to perform thermal cycling, after which the PCR result was read by electrophoresis using a 1.5% agarose gel. The gel containing the PCR product was examined using an ultraviolet source to determine the presence of the product with the Ladder unit.

Preparation of ZnO-NPs and infection of the animals

The nanocomposite (ZnO-NPs) was prepared in the form of a stock solution. One gram of ZnO-NPs was dissolved in a liter of distilled water and sterilized in an autoclave. The solution was then mixed using an ultrasonic homogenizer for 15 minutes to prevent the agglomeration of these materials, and the concentrations were prepared at 5, 15, and 20 mg/kg. Thirty Swiss Balb/C mice, aged 21 days and weighing 20 to 25 g, were used. The mice were placed in plastic cages prepared for this purpose in the animal house of the Department of Biology at Al-Qadisiya University, and the appropriate conditions were provided: temperature, ventilation, lighting, water, and continuous feeding. Before starting to dose the mice, their absence of intestinal parasites was confirmed by examining the stool. The, mice were divided into six groups containing five mice each. Groups 1, 2, and 3 in which mice were dosed with 1 mL of the specified dose 1 × 103 oocysts/mouse from suspended oocysts of the parasite C. parvum and then dosed orally with 5, 15, 20 mg/kg of ZNOPs, respectively. The mice in group 4 were dosed with 1 mL of the specified dose: 1 × 103 oocytes/mouse from suspended oocysts of C. parvum and then dosed with 10 mg/kg of nitazoxanide. Group 5 represented the negative control group, dosed with 1 mL of physiological saline, and group 6 comprised the positive control group, dosed with 1 mL of the specified dose 1 × 103 oocysts/mouse from suspended oocysts of C. parvum parasite and left untreated. The feces of mice were examined starting from the second day after dosing until the oocysts appeared to confirm the presence of oocysts. The oocysts were counted after isolating and purifying them, and the therapeutic efficacy was calculated according to Xiao et al. [18].
Therapeutic efficacy=Average no.of oocysts in the positive control - average no.of oocysts in the treated groupAverage no.of oocysts in the positive control×100

Statistics analysis

A completely randomized design was used in a two-factor experiment (concentrations and time periods) for five replicates. The results were tested according to least significance differences and at a probability level of p < 0.05.

Results

The results of the experimental infection for laboratory mice administered a dose of 1 × 103 oocysts/laboratory mouse. The rate of infection with the C. parvum reached 100%. The infection of the mice was confirmed by examining the stools using the modified Ziehl- Nelson stain, where the oocysts were observed, which appeared spherical or oval in shape and red in color (Fig. 1). The, oocysts were also confirmed by N-PCR, as shown in Fig. 2. The oocysts were observed on days four and five after dosing (prepatent period).
The rate of excretion of oocysts of C. parvum varied after treatment (Table 1) because the number of excreted oocysts decreased as the concentration and treatment period were increased. Mice infected with the oocysts and treated with zinc nanoparticles at 5 mg/kg continued to excrete oocysts throughout the seven-day treatment period, achieving treatment efficiencies of 4.03%, 9.89%. 15.48%, 25.33%, 28.00%, 59.72%, and 45%, respectively . At 15 mg/kg, a noticeable decrease in the number of excreted oocysts was observed, especially on the sixth and seventh days of treatment, because the number reached 600 oocysts/mL, with 96.31% and 100% efficiency, respectively. At 20 mg/mL the number of excreted oocysts decreased from the first day of treatment, with the mice completely stopping excreting oocysts on the fifth, sixth, and seventh days of treatment, with a therapeutic efficiency of 23.04%, 39.06%, 83.67%, 93.81%, 100%, 100%, and 100%, respectively , with significant differences between the groups. Hence, 20 mg/mL is considered the most efficient concentration. The results from the group treated with nitazoxanide and the control groups were at the probability level of p ≤ 0.05.

Discussion

Cryptosporidiosis is a zoonotic pathogen and a health problem in humans and animals [19]. Nitazoxanide is the only and most widely approved treatment by the Food and Drug Administration [20] because it inhibits the enzyme pyruvate ferredoxin oxidoreductase in the anaerobic metabolic pathway. This drug is ineffective for malnourished children and immunocompromised individuals [21].
Zinc nanoparticles have gained an important place in various medical and pharmaceutical sciences, in addition to their potential use as anti-parasitic agents, owing to their bio-catalytic activities [22]. These antimicrobial properties may be manifested in two ways: by stimulating programmed cell death by inhibiting cell growth, or by zinc nanoparticles producing H2O, which leads to increased oxidative stress, release of zinc ions, and penetration of the cell wall [23,24].
The mice were infected with C. parvum, no other species of the genus Cryptosporidium, because it infects humans and other mammals. The results showed that an experimental infection occurred in all groups dosed with the parasite. Most cases of infection were of the mild type because the number of oocysts ranged between one and four cysts in the prepared swabs. The first oocyst appeared in the feces of mice on days four to five after dosing, which concurs with Khashan et al. [24] It is not consistent with the results of [25], which indicated the appearance of oocysts at a high rate on the second day of infection. HSP70 was chosen because it plays a role in protein folding and transport, as well as the assembly and disassembly of protein complexes, which affects the thermotolerance of animals.
The results of the current study indicated the use of zinc nanoparticles as a treatment for mice infected with oocysts for one week. The effects of the three concentrations (5, 15, and 20 mg/kg) varied in reducing or decreasing the number of oocysts excreted in the feces of the experimentally infected mice, where 20 mg/kg was the best in completely reducing the oocysts on the fifth day of treatment with a therapeutic efficiency of 100%, i.e., the mice completely stopped producing oocysts compared to the positive control group, which continued producing oocysts until the seventh day. This concentration was also closer to the group treated with 10 mg/kg of nitazoxanide, which achieved 100% therapeutic efficacy on the fourth day of treatment. These results are similar to those reported by Vaidya et al. [16], who confirmed that ZnO-NPs were more effective in dissolving the oocysts of C. parvum than silver nanoparticles. These results are similar to those of Hamdy et al. [26], who used ZnO-NPs loaded with nitazoxanide and Allium sativum to treat experimental cryptosporidiosis.
The effectiveness of zinc nanoparticles may be due to their greater solubility, which was confirmed by Kermanizadeh et al. [27]. Zinc nanoparticles are characterized by their ability to penetrate the wall of the oocysts and disrupt the glycoproteins present in the wall of the oocyst, in addition to the small size of these particles that enables them to penetrate the cell membrane and thus cause direct damage [28-30]. Czyżowska amd Barbasz [31] reported that zinc particles bind to the DNA of C. parvum, which affects metabolic processes.
At 15 mg/kg, therapeutic efficiency was achieved on the sixth and seventh days with a therapeutic efficiency of 96.31% and 100%, respectively, while the mice treated with 5 mg/kg continued to excrete oocysts until the seventh day of treatment. This may be because 5 mg/kg is too low compared to 15 mg/kg and 20 mg/kg. In general, an inverse relationship was observed between the rate of the number of oocysts excreted in the feces of infected mice and the concentrations used.

Notes

The authors declare no conflict of interest.

Author’s Contributions

Conceptualization: all authors; Data curation: all authors;Formal analysis: Anah SaaA, Mayih HS; Funding acquisition: Mayih HS, Anah SadA; Investigation: all authors; Methodology: all authors; Project administration: Anah SadA; Resources: all authors; Software: Anah SaaA; Supervision: Mayih HS, Anah SadA; Validation: Anah SaaA; Visualization: Anah SaaA; Writing-original draft: Anah SadA; Writing-review & editing: Anah SadA.

Acknowledgments

The author is thankful to the management of the University of Al-Qadisiyah, for their continuous encouragement.

Fig. 1.
Oocysts of Cryptosporidium parvum isolated from the feces of experimentally infected mice (100×).
kjvr-20250015f1.jpg
Fig. 2.
Electrophoresis of the amplified HSP70 gene in a nested- PCR reaction on 1.5% agarose gel. Lane M: DNA ladder; lanes (1-10): expanded bands of HSP70 gene (approximately 370 bp).
kjvr-20250015f2.jpg
Table 1.
Means of oocyst numbers after different periods of giving zinc oxide nanoparticles (ZN-OPs) with therapeutic efficiency
Group No. of mice (n = 30) Treatment (mg/kg) Means of oocysts numbers (d)/therapeutic efficacy
1 2 3 4 5 6 7
Group 1 5 5 (Zn-NPs) 5,300 (4.03) 5,190 (9.89) 5,200 (15.48) 4,950 (25.33) 4,547 (28.00) 3,500 (59.72) 2,900 (45.00)
Group 2 5 15 (Zn-NPs) 5,111 (7.45) 4,450 (22.74) 3,700 (39.30) 2,000 (69.83) 690 (89.10) 320 (96.31) 0 (100)
Group 3 5 20 (Zn-NPs) 4,250 (23.04) 3,510 (39.06) 1,000 (83.67) 0 (100) 410 (93.81) 0 (100) 0 (100)
Group 4 5 10 (Nitazoxanide) 2,411 (56.00) 1,150 (80.03) 853 (36.13) 0 (100) 0 (100) 0 (100) 0 (100)
Group 5 5 Physiological saline 5,523 (0) 5,760 (0) 6,153 (0) 6,630 (0) 6,332 (0) 8,690 (0) 5,300 (0)
Group 6 5 1 × 103 Oocysts 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)

Numbers (1-7) represent treatment days, least significance difference of p < 0.05 in the first day: 240; in the second day: 164; in the third day: 329; in the fourth day: 61.82; in the fifth day: 151.9; in the sixth day: 77.2; in the seventh day: 58.9. Groups 1-4 were dosed with 1 mL of the specified dose 1 × 103 oocysts/mouse from suspended oocysts of the parasite C. parvum and then dosed with ZN-OPs or nitazoxanide.

References

1. Krumkamp R, Aldrich C, Maiga-Ascofare O, Mbwana J, Rakotozandrindrainy N, Borrmann S, et al. Transmission of cryptosporidium species among human and animal local contact networks in sub-Saharan Africa: a multicountry study. Clin Infect Dis. 2021;72:1358-1366.
crossref pmid pmc pdf
2. Dong S, Yang Y, Wang Y, Yang D, Yang Y, Shi Y, et al. Prevalence of cryptosporidium infection in the global population: a systematic review and meta-analysis. Acta Parasitol. 2020;65:882-889.
crossref pmid pdf
3. Pinto DJ, Vinayak S. Cryptosporidium: host-parasite interactions and pathogenesis. Curr Clin Microbiol Rep. 2021;8:62-67.
crossref pmid pmc pdf
4. Osman M, Benamrouz S, Guyot K, Baydoun M, Frealle E, Chabe M, et al. High association of Cryptosporidium spp. infection with colon adenocarcinoma in Lebanese patients. PLoS One. 2017;12:e0189422.
crossref pmid pmc
5. Singh A, Jain D, Upadhyay MK, Khandelwal N, Verma HN. Green synthesis of silver nanoparticles using Argemone mexicana leaf extract and evaluation of their antimicrobial activities. Dig J Nanomater Bios. 2010;5:483-489.
6. Vetchinkina E, Loshchinina E, Kupryashina M, Burov A, Pylaev T, Nikitina V. Green synthesis of nanoparticles with extracellular and intracellular extracts of basidiomycetes. PeerJ. 2018;6:e5237.
crossref pmid pmc pdf
7. Altammar KA. A review on nanoparticles: characteristics, synthesis, applications, and challenges. Front Microbiol. 2023;14:1155622.
crossref pmid pmc
8. Plachá D, Jampílek J. Chapter 4: Impact of nanoparticles on protozoa. In: Rai M, Patel M, Patel R, eds. Nanotechnology in Medicine: Toxicity and Safety. Springer Nature; 2021: pp 67-108.
9. Cameron P, Gaiser BK, Bhandari B, Bartley PM, Katzer F, Bridle H. Silver nanoparticles decrease the viability of Cryptosporidium parvum oocysts. Appl Environ Microbiol. 2015;82:431-437.
crossref pmid pmc pdf
10. Shah S, Shah SA, Faisal S, Khan A, Ullah R, Ali N, et al. Engineering novel gold nanoparticles using Sageretia thea leaf extract and evaluation of their biological activities. J Nanostructure Chem. 2022;12:129-140.
crossref pdf
11. Faisal S, Jan H, Shah SA, Shah S, Khan A, Akbar MT, et al. Green synthesis of zinc oxide (ZnO) nanoparticles using aqueous fruit extracts of Myristica fragrans: their characterizations and biological and environmental applications. ACS Omega. 2021;6:9709-9722.
crossref pmid pmc pdf
12. Begum F, Me HM, Christov M. The role of zinc in cardiovascular disease. Cardiol Rev. 2022;30:100-108.
crossref pmid
13. Anah SA, Anah SA, Al-Khalidy KA. Antiparasitic activity of zinc oxide nanoparticles against Eimeria tenella in broilers experimentally infected. Korean J Vet Res. 2022;62:e30.
crossref pdf
14. Dkhil MA, Al-Quraishy S, Wahab R. Anticoccidial and antioxidant activities of zinc oxide nanoparticles on Eimeria papillata-induced infection in the jejunum. Int J Nanomedicine. 2015;10:1961-1968.
crossref pmid pmc
15. Nazir S, Rabbani A, Mehmood K, Maqbool F, Shah GM, Khan MF, et al. Antileishmanial activity and cytotoxicity of ZnO-based nano-formulations. Int J Nanomedicine. 2019;14:7809-7822.
pmid pmc
16. Vaidya A, Bankier C, Johnston H, Bridle H. Nanoparticle lysis of Cryptosporidium oocysts. Methods Protoc. 2024;7:66.
crossref pmid pmc
17. Lazo A, Barriga OO, Redman DR, Bech-Nielsen S. Identification by transfer blot of antigens reactive in the enzyme-linked immunosorbent assay (ELISA) in rabbits immunized and a calf infected with Cryptosporidium sp. Vet Parasitol. 1986;21:151-163.
crossref pmid
18. Xiao L, Saeed K, Herd RP. Efficacy of albendazole and fenbendazole against Giardia infection in cattle. Vet Parasitol. 1996;61:165-170.
crossref pmid
19. Al-Radadi NS, Hussain T, Faisal S, Ali Raza Shah S. Novel biosynthesis, characterization and bio-catalytic potential of green algae (Spirogyra hyalina) mediated silver nanomaterials. Saudi J Biol Sci. 2022;29:411-419.
crossref pmid pmc
20. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007;51:868-876.
crossref pmid pmc pdf
21. Shoultz DA, de Hostos EL, Choy RK. Addressing Cryptosporidium infection among young children in low-income settings: the crucial role of new and existing drugs for reducing morbidity and mortality. PLoS Negl Trop Dis. 2016;10:e0004242.
crossref pmid pmc
22. Khan MI, Shah S, Faisal S, Gul S, Khan S, Abdullah , et al. Monotheca buxifolia driven synthesis of zinc oxide nano material its characterization and biomedical applications. Micromachines (Basel). 2022;13:668.
crossref pmid pmc
23. Sasai M, Pradipta A, Yamamoto M. Host immune responses to Toxoplasma gondii. Int Immunol. 2018;30:113-119.
crossref pmid pdf
24. Khashan KS, Sulaiman GM, Hussain SA, Marzoog TR, Jabir MS. Synthesis, characterization and evaluation of anti-bacterial, antiparasitic and anti-cancer activities of aluminum-doped zinc oxide nanoparticles. J Inorg Organomet Polym. 2020;30:3677-3693.
crossref pdf
25. Moawad HS, Hegab MH, Badawey MS, Ashoush SE, Ibrahim SM, Ali AA. Assessment of chitosan nanoparticles in improving the efficacy of nitazoxanide on cryptosporidiosis in immunosuppressed and immunocompetent murine models. J Parasit Dis. 2021;45:606-619.
crossref pmid pmc pdf
26. Hamdy DA, Ismail MA, El-Askary HM, Abdel-Tawab H, Ahmed MM, Fouad FM, et al. Newly fabricated zinc oxide nanoparticles loaded materials for therapeutic nano delivery in experimental cryptosporidiosis. Sci Rep. 2023;13:19650.
crossref pmid pmc pdf
27. Kermanizadeh A, Gaiser BK, Hutchison GR, Stone V. An in vitro liver model--assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanomaterials. Part Fibre Toxicol. 2012;9:28.
crossref pmid pmc
28. Sabourian P, Yazdani G, Ashraf SS, Frounchi M, Mashayekhan S, Kiani S, et al. Effect of physico-chemical properties of nanoparticles on their intracellular uptake. Int J Mol Sci. 2020;21:8019.
crossref pmid pmc
29. Siddiqi KS, Ur Rahman A, Husen A. Properties of zinc oxide nanoparticles and their activity against microbes. Nanoscale Res Lett. 2018;13:141.
crossref pmid pmc pdf
30. Prasad AR, Williams L, Garvasis J, Shamsheera KO, Basheer SM, Kuruvilla M, et al. Applications of phytogenic ZnO nanoparticles: a review on recent advancements. J Mol Liq. 2021;331:115805.
crossref
31. Czyżowska A, Barbasz A. A review: zinc oxide nanoparticles: friends or enemies? Int J Environ Health Res. 2022;32:885-901.
crossref pmid


About
Policy
Browse articles
For contributors
Editorial Office
#401-1, 85 Bldg., College of Veterinary Medicine, Seoul National University
1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
Tel: +82-2-880-1229    Fax: +82-2-878-9762    E-mail: jvs@ksvs.or.kr                

Copyright © 2025 by The Korean Society of Veterinary Science.

Developed in M2PI

Close layer
prev next